Additional 120 consecutive HER2+ breast cancer cases receiving neoadjuvant chemotherapy combined with trastuzumab as the validation set, their ROC curve and Youden index confirmed the rationality of 10% as the cutoff value for tpCR (Fig. S1b). The gene discussed is ERBB2; the disease is breast cancer.